A study published this month in the peer-reviewed journal Frontiers in Neurology found that cannabidiol (CBD) may significantly reduce seizure frequency and improve quality of life in children with drug-resistant epilepsy (DRE).
Researchers from the University of Messina conducted an observational, retrospective study involving 15 pediatric patients with pharmacoresistant epilepsy. The children, who had a mean age of just over 12 years, were treated with CBD as an add-on therapy to existing antiseizure medications.
Of the 15 participants, 11 experienced a reduction in seizures after at least six months of CBD treatment. Seven were considered responders—showing more than 50% seizure reduction—including two who became completely seizure-free. Five were classified as partial responders with a 30% to 50% reduction in seizure frequency. CBD was used on-label in eight children (for conditions such as Dravet Syndrome, Lennox-Gastaut Syndrome, and Tuberous Sclerosis Complex) and off-label in the remaining seven.
Beyond seizure control, the study also noted improvements in the patients’ social engagement and daily functioning, as reported by caregivers and measured using the Clinical Global Impression scale. MRI findings revealed brain abnormalities in many participants, with notable response rates even among those with cortical malformations.
The researchers concluded that CBD was well tolerated and may serve as a promising therapeutic option for pediatric patients with otherwise intractable seizures, offering both seizure relief and quality-of-life benefits for families.
More articles from The Marijuana Herald can be found below.
